Anti-C4d chimeric antigen receptor regulatory T cells suppressed allograft rejection in ABO-incompatible heart transplantation  

作　　者：Sun-Kyung Lee Jerome Han Honglin Piao Nara Shin Joon Young Jang Ji-Jing Yan Hyori Kim Junho Chung Jaeseok Yang 

机构地区：[1]Biomedical Research Institute,Seoul National University Hospital,Seoul 03080,Republic of Korea [2]Department of Medicine,Graduate School,Seoul National University College of Medicine,Seoul 03080,Republic of Korea [3]Department of Biochemistry and Molecular Biology,Seoul National University College of Medicine,Seoul 03080,Republic of Korea [4]Department of Biomedical Science,Seoul National University College of Medicine,Seoul 03080,Republic of Korea [5]Cancer Research Institute,Seoul National University College of Medicine,Seoul 03080,Republic of Korea [6]Division of Nephrology,Department of Internal Medicine,Yonsei University College of Medicine,Seoul 03722,Republic of Korea [7]Convergence Medicine Research Center,Asan Medical Center,Seoul 05505,Republic of Korea

出　　处：《Genes & Diseases》2022年第1期1-4,共4页基因与疾病（英文）

基　　金：This study was supported by a grant from the Ministry of Health and Welfare(No.HI18C0532),Republic of Korea;

摘　　要：ABO blood group-incompatible(ABOi)transplantation has been developed to overcome the serious problem of donor organ shortage.However,antibody-mediated rejection(ABMR)remains as the main limitation to successful ABOi transplantation.Introduction of desensitization treatment improved the outcomes of ABOi transplantation by suppressing ABMR;however,this strong,nonspecific immunosuppression also increases infectious complications.Recently,chimeric antigen receptor regulatory T cells(CAR Tregs)were developed to improve the antigen specificity,viability,and suppressive activity of Tregs.C4d deposition is a marker of ABMR and is also found in most ABOi allograft tissues.Based on these findings,we developed anti-C4d CAR Tregs to suppress ABMR in ABOi allografts.

关 键 词：C4D ABO ALLOGRAFT 

分 类 号：R654.2[医药卫生—外科学]